- In December 2023, Roche has acquired select parts of LumiraDx’s innovative Point of Care technology, enhancing its diagnostics portfolio. This acquisition enables faster, more affordable testing across multiple disease areas. The integration of LumiraDx’s platform will improve patient access to timely, accurate diagnostic results in decentralized healthcare settings globally
- In January 2025, Danaher Corporation has formed an investment partnership with Innovaccer Inc., a healthcare AI company. This collaboration aims to accelerate the adoption of precision diagnostics and value-based care by providing healthcare providers with unified patient data and advanced analytics, improving patient outcomes through personalized, timely interventions
- In February 2025, BD has announced plans to separate its Biosciences and Diagnostic Solutions businesses to enhance strategic focus, drive growth, and unlock value. The move aims to create two independent entities, each better positioned to capitalize on their respective markets. This decision underscores BD's commitment to strengthening its leadership in healthcare innovation while optimizing operational efficiencies for long-term success
- In November 2023, Binx Health has partnered with Fisher Healthcare to expand distribution of the FDA-cleared binx io, a molecular point-of-care platform for detecting chlamydia and gonorrhea. This system provides lab-quality results in about 30 minutes, improving timely diagnoses and enabling clinicians to test and treat patients during a single visit, enhancing care access
- In April 2023, Binx Health is expanding its commercial organization to meet the growing demand for its FDA-cleared, CLIA-waived binx io platform, which detects chlamydia and gonorrhea in 30 minutes. This molecular point-of-care solution offers central lab-equivalent performance and addresses the urgent need for accessible, timely STI testing, improving care across the U.S.
Frequently Asked Questions
Companies such as F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Siemens Healthineers AG (Germany), BD (Becton, Dickinson and Company) (U.S.), and Abbott (U.S.) are major players in global point-of-care testing (POCT) market.
In January 2025, Genrobotics launched India's first pediatric robotic gait trainer, G-Gaiter, helping children with mobility impairments regain walking abilities through personalized therapy, enhancing rehabilitation and promoting better mobility outcomes.
The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Belgium, Sweden, Denmark, Finland, Norway, Poland, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Vietnam, Philippines, Taiwan, New Zealand, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Kuwait, Israel, Qatar, Oman, Bahrain, and rest of Middle East & Africa.
